• 1. Evolving better nanoparticles: Genetic algorithms for optimising cluster geometries
  Dalton Trans., 2003, 4193-4207
• 2. Excimer formation effects and trap-assisted charge recombination loss channels in organic solar cells of perylene diimide dimer acceptors?
  Min Kim,Jae-Joon Lee,Tengling Ye,Panagiotis E. Keivanidis,Kilwon Cho J. Mater. Chem. C, 2020,8, 1686-1696
• 3. Elusive 2-aminofuran Diels–Alder substrates for a straightforward synthesis of polysubstituted anilines?
  Ana G. Neo,Ana Bornadiego,Jesús Díaz,Stefano Marcaccini,Carlos F. Marcos Org. Biomol. Chem., 2013,11, 6546-6555
• 4. Excellent kinetics of single-phase Gd-doped ceria fuel electrodes in solid oxide cells?
  Andreas Nenning,Manuel Holzmann,Jürgen Fleig,Alexander K. Opitz Mater. Adv., 2021,2, 5422-5431
• 5. Evolution of shape, size, and areal density of a single plane of Si nanocrystals embedded in SiO2 matrix studied by atom probe tomography
  Bin Han,Yasuo Shimizu,Gabriele Seguini,Celia Castro,Gérard Ben Assayag,Koji Inoue,Yasuyoshi Nagai,Sylvie Schamm-Chardon,Michele Perego RSC Adv., 2016,6, 3617-3622

• Solvents and Organic Chemicals Organic Compounds Organic acids and derivatives Carboxylic acids and derivatives Amino acids, peptides, and analogues Amino acids and derivatives

Recent Advances in the Study of rac Kainic Acid (73209-05-9) and Its Applications in Neuropharmacology

Kainic acid (KA) and its derivatives, including rac Kainic Acid (CAS: 73209-05-9), have been extensively studied for their role as potent neuroexcitatory agonists at glutamate receptors, particularly the kainate subtype. Recent research has focused on understanding the molecular mechanisms of rac Kainic Acid's action, its potential therapeutic applications, and its implications in neurodegenerative diseases. This research brief synthesizes the latest findings on rac Kainic Acid, highlighting its chemical properties, biological activity, and emerging applications in neuroscience and drug development.

A significant body of recent literature has explored the structural and functional aspects of rac Kainic Acid. Studies have demonstrated that rac Kainic Acid binds selectively to kainate receptors, leading to neuronal excitation and, in some cases, excitotoxicity. This property has been leveraged in experimental models of epilepsy and neurodegenerative disorders such as Alzheimer's and Parkinson's diseases. Notably, a 2023 study published in *Neuropharmacology* elucidated the differential effects of rac Kainic Acid enantiomers on receptor binding affinity, providing insights into the stereochemistry of its neuroactive properties.

In addition to its role in basic research, rac Kainic Acid has been investigated for its potential in drug discovery. Researchers have synthesized novel analogs of rac Kainic Acid to modulate its pharmacological profile, aiming to reduce its neurotoxic effects while retaining its therapeutic potential. For instance, a recent *Journal of Medicinal Chemistry* article reported the development of a rac Kainic Acid derivative with improved blood-brain barrier permeability and reduced cytotoxicity, opening new avenues for treating neurological disorders.

Another critical area of research involves the use of rac Kainic Acid in studying synaptic plasticity and neuronal network dynamics. Advanced imaging techniques, such as two-photon microscopy and optogenetics, have been employed to visualize the real-time effects of rac Kainic Acid on neuronal circuits. These studies have provided unprecedented insights into the mechanisms of excitatory neurotransmission and the pathophysiology of epilepsy.

Despite its promise, the use of rac Kainic Acid in clinical settings remains limited due to its potential for inducing excitotoxic damage. However, ongoing research aims to mitigate these risks through targeted delivery systems and receptor-specific modulators. A 2024 review in *Trends in Pharmacological Sciences* highlighted the progress in developing rac Kainic Acid-based therapeutics with enhanced safety profiles, emphasizing the need for further preclinical validation.

In conclusion, rac Kainic Acid (73209-05-9) continues to be a valuable tool in neuropharmacology, offering insights into glutamate receptor function and neuronal excitability. Recent advancements in its structural modification and application in disease models underscore its potential as a therapeutic agent. Future research should focus on optimizing its pharmacological properties and translating these findings into clinical applications for neurodegenerative and psychiatric disorders.

• 487-79-6(Kainic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)